Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 12,865 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07564557Recruiting
Guided surgery for small deep lung cancers
This trial tests a new surgical technique to remove small, early-stage lung cancers that are located deep within the lung tissue. The goal is to remove only the affected area while preserving as much healthy lung as possible.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07563205Recruiting
Study of Chemotherapy and Amivantamab for Advanced Lung Cancer
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
Aix-en-ProvenceAges 18 years+ - NCT07561840Recruiting
Exercise Training After Stomach or Esophagus Cancer Surgery
This study tests whether a guided exercise program helps people recover better after surgery for esophageal or gastric (stomach) cancer. Researchers will track your strength, fitness, and quality of life over time.
Hirakata, OsakaAges 18 years+ - NCT06735326RecruitingPhase 2
Fluzoparib and Bevacizumab Before Surgery for Advanced Ovarian Cancer
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
Jinan, ShandongAges 18 years+ - NCT06276868RecruitingPhase 2
Darsilide plus hormone therapy and double antibody for breast cancer
This trial tests if adding a new drug (darsilide) to standard hormone therapy and two antibodies (trastuzumab and pertuzumab) before surgery can improve outcomes for women with HR-positive, HER2-positive breast cancer that hasn't spread.
Henan, HenanAges 18–70 - NCT07552467Recruiting
PET Imaging Scan for Detecting Cancer Using New Radioactive Tracer
This study tests a new type of imaging scan (PET/CT or PET/MR) that uses a radioactive tracer to help doctors better detect and diagnose various cancers. The scan targets a specific protein found in tumors, which may help identify cancer more accurately than standard imaging.
Wuhan, HubeiAges 18 years+ - NCT06742021Recruiting
MRI test to predict immune therapy response in lung cancer
This trial uses a special MRI technique (4D FreeBreathing) to see if it can predict how well immune therapy or targeted therapy works for your lung cancer. It may help doctors choose the best treatment for you more quickly.
Kunming, YunnanAges 18–75 - NCT07545811RecruitingPhase 1
JANX014 for Advanced Prostate Cancer
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT07545122RecruitingPhase 1
Testing CT-202 for Triple Negative Breast, Colorectal, and Bladder Cancers
This early-stage trial tests a new antibody drug called CT-202 in patients whose cancer has come back after standard treatments. The drug is designed to target cancer cells that have a specific protein called Nectin-4, and may help the immune system fight the cancer.
Wahroonga, New South WalesAges 18 years+ - NCT07543601Recruiting
Better COPD care for people evaluated for lung cancer
This trial tests whether people being checked for possible lung cancer can also get improved care for a breathing condition called COPD (chronic obstructive pulmonary disease). It focuses on patients whose lung function tests show airflow problems.
VejleAges 18 years+ - NCT04214990RecruitingPhase 3
Aspirin after early stomach precancer or early cancer removal
This trial tests whether taking aspirin after endoscopic removal of an early stomach condition can lower the chance of the cancer coming back or progressing. You may be considered if your early stomach findings were fully removed and you’re able to avoid certain medications that raise bleeding risk.
BusanAges 19–70 - NCT07542262Enrolling by invitationPhase 2
Low-dose immunotherapy for advanced colorectal and stomach cancer
This study tests a lower dose of immunotherapy in patients with colorectal or stomach cancer that has spread or cannot be removed by surgery. The cancer must have a specific genetic feature (MSI/dMMR). The goal is to see if this approach works well with fewer side effects.
MoscowAges 18 years+ - NCT07531329Recruiting
Delayed PSMA imaging to detect aggressive prostate cancer
This study tests whether a special type of imaging scan (PSMA PET/CT with delayed imaging) can better identify aggressive prostate cancer in men who haven't had a biopsy yet. The goal is to help doctors decide who really needs a biopsy and avoid unnecessary procedures.
Lanzhou, GansuAges 18 years+ - NCT07532538Recruiting
Machine learning tool to predict head and neck cancer risk
This study tests a computer program designed to help doctors predict which head and neck lesions (abnormal tissue growths) might be cancerous. Researchers will use your medical information and throat imaging to teach the program, which could help catch cancer earlier.
Nanjing, JiangsuAges 18–100 - NCT06755866Recruiting
Predicting chemo-radiation response with improved MRI for esophageal cancer
This trial uses a special MRI technique to see if it can predict how well esophageal cancer responds to chemo-radiotherapy before surgery. It may help doctors choose the best treatment plan for you.
Kunming, YunnanAges 18–80 - NCT07510802RecruitingPhase 1/Phase 2
CAR-NK cells for advanced HER2+ or triple-negative breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
Shenzhen, GuangdongAges 18–75 - NCT07510321Recruiting
A study of FL-261 imaging for cancer diagnosis
This trial tests a new imaging agent called FL-261 to help doctors see and stage cancers more clearly. If you have a known or suspected cancer like lung, colon, or head and neck cancer, this study may improve how your cancer is evaluated.
Wuhan, HubeiAges 18 years+ - NCT07510724Recruiting
Real-world study of Tislelizumab for lung cancer
This trial collects information on how well the immunotherapy drug Tislelizumab works for different types of lung cancer. It is meant for people whose doctor already decided to prescribe this drug as part of their care.
Sankt Pölten, Lower AustriaAges 18 years+ - NCT06307886Recruiting
Uterine manipulator in endometrial cancer surgery
This trial compares survival rates for patients with early-stage endometrial cancer who have laparoscopic hysterectomy with or without a uterine manipulator (a tool used during surgery).
IstanbulAges 18–75 - NCT07505797Recruiting
Ultrasound imaging study for suspicious breast lesions
This study is testing a new ultrasound device (ATUSA) to see how well it can image breast lesions that have been classified as suspicious (BI-RADS 4 or 5). If you have a recent finding that needs further evaluation, this research might help improve detection methods.
Sacramento, CaliforniaAges 18–94 - NCT07505173RecruitingPhase 2
Targeted radiation plus osimertinib for brain metastases from EGFR-mutant lung cancer
This trial tests adding a brain-sparing radiation technique to the targeted therapy drug osimertinib for people with EGFR-mutant lung adenocarcinoma that has spread to the brain and is causing symptoms. The goal is to see if this combination can better control the brain tumors while protecting the hippocampus, a key memory area.
TianjinAges 18–75 - NCT07501650RecruitingPhase 1
Pembrolizumab plus ultrasound bubbles for head and neck cancer
This trial combines the immunotherapy drug pembrolizumab (Keytruda) with a special ultrasound technique that uses tiny bubbles to make the treatment work better. It is for people with HPV-negative head and neck cancer that has come back or spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07503496Recruiting
Biobran supplement for breast cancer chemo support
This trial tests if a supplement called Biobran (made from rice bran) can help support people with breast cancer who are receiving chemotherapy. It may reduce side effects or improve treatment tolerance.
TaichungAges 20–65 - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 12,865 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.